These innovative molecules represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://esmeejaqi409913.blogdon.net/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-55136139